Next-Generation Sequencing Market Size to Reach US$ 31,411.3 Mn, Introduction of Rapid Sequencing Technologies Drives the Market: Fortune Business…

August 17, 2020 11:38 ET | Source: Fortune Business Insights

Pune, Aug. 17, 2020 (GLOBE NEWSWIRE) -- The global next-generation sequencing market is forecast to exhibit a remarkable CAGR as the next-generation sequencing platform allows effective sequencing of millions of DNA molecules. Fortune Business Insights in a new report, titled Next-Generation Sequencing: Global Market Analysis, Insights and Forecast, 2019-2026 offers a detailed analysis of the competitive landscape and market dynamics.

The demand for cost-effective, accurate, and fast DNA sequencing technologies is increasing and this is further giving rise to the dominance of next-generation sequencing platforms. This will further give rise to advanced sequencing technologies for clinical purposes, which is anticipated to drive the market. Increasing advancements in bioinformatics are likely to increase the adoption of next-generation sequencing platforms to facilitate the diagnosis of rare diseases.

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/next-generation-sequencing-ngs-market-101000

As per the report, the global market is expected to rise at a ferocious CAGR of 22.2% between 2018 and 2026. In 2018, the market was worth US$ 6,335.2 Mn and the market will be a howling success as it is projected to reach US$ 31,411.3 Mn by 2026. The demand for next-generation sequencing methodologies is increasing rapidly across several applications such as diagnostics, clinical research among others.

The global economy is in absolute turmoil because of the COVID-19 pandemic outbreak. Some industries remain largely unaffected by the outbreak, some are thriving, but most are in doldrums. Although the healthcare industry is flourishing, certain markets within the industry are experiencing staggered growth. Wading through these troubled times is a difficult task and Fortune Business Insights aims at equipping your business with the most comprehensive market insights, collated and analyzed by our expert and experienced research team.

Click here to get the short-term and long-term impact of COVID-19 on this market.

Please visit: https://www.fortunebusinessinsights.com/industry-reports/next-generation-sequencing-ngs-market-101000

Demand for Next-Generation Sequencing Services to Rise at a High Pace

Next-generation sequencing products encompass instruments, consumables, and software. According to the findings from the report, the next-generation sequencing product segment is anticipated to lead the market over the forecast period. This is ascribable to some primary factors such as new product launches, high usage of consumables, and easy availability.

Apart from next-generation sequencing products, next-generation sequencing services are expected to grow at a higher CAGR during the forecast period. The need for novel platforms regarding advancements in bioinformatics and fast DNA data interpretation are paving way for start-ups, especially for next-generation sequencing services. With the introduction of next-generation sequencing, the cost of sequencing has reduced over the years.

This is positively impacting the growth of this segment. Furthermore, the adoption of next-generation sequencing-based testing is increasing across the world. This, coupled with attractive healthcare reimbursement policies, is expected to drive the segments growth in the projected period.

Quick Buy - Next-Generation Sequencing Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/101000

North America Leads the Way Owing to Active Government Support

Among regions, North America is anticipated to lead the global next-generation sequencing market through the forecast duration. Rapid developments in precision medicine, next-generation DNA sequencing, and diagnostics are creating growth opportunities for the market. The market is likely to expand as companies in the biotechnology sector are continuously involving in research and development (R&D) activities, which fuels the market demand. Adapative Technologies developed a next-generation sequencing diagnostic test called ClonoSEQ for patients suffering from acute lymphoblastic leukemia or ALL and minimal residual disease or MRD. The test received FDA approval in September 2018, which in turn, contributes to the growth of the market in North America.

Increasing investments in precision medicine and a growing number of strategic collaborations are driving the market in Europe. Driven by these factors, the market in this region is expected to expand in the forecast period. Apart from these two regions, Asia Pacific is expected to expand at a remarkable growth on account of rising geriatric population and growing awareness about reproductive health.

Saphetor SA and Swift Biosciences Inc.s Partnership Aims to Target Next-Generation Sequencing Panels

Strategic partnerships and new product launches are increasingly adopted by companies as these help them to maintain their position in the market. Some of the industry developments are mentioned below:

Companies such as Illumina, Inc., Thermo Fisher Scientific Inc., and F. Hoffmann-La Roche Ltd are likely to lead in the global next-generation sequencing market. This is mainly on account of their strong geographical presence and diversified product portfolio. Moreover, Illumina was leading in the global market owing to its rising product sales. New product launches also helped the company to strengthen its market position.

Some of the other players functioning in the global market are Agilent Technologies, Inc., BGI, PerkinElmer Inc., QIAGEN, Eurofins Scientific, PierianDx, Macrogen, Inc. among others.

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/next-generation-sequencing-ngs-market-101000

Next-Generation Sequencing Market Segmentation:

By Type

Products

Instruments & Software

Consumables

Services

By Application

Diagnostics

Research

Others

By End User

Research Institutes

Healthcare Facilities & Diagnostic Centers

Pharmaceutical & Biotechnological Companies

Contract Research Organization (CROs)

By Geography

North America (the USA and Canada)

Europe (UK, Germany, France, Italy, Spain, and Rest of Europe)

Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)

Latin America (Brazil, Mexico, and Rest of Latin America)

Middle East & Africa (South Africa, GCC, and Rest of the Middle East & Africa)

Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/next-generation-sequencing-ngs-market-101000

Have a Look at Related Reports:

Genomics Market Share and Global Trend By Type (Products, Services), Technology (Polymerase Chain Reaction, Next-generation Sequencing, Microarray, Sanger Sequencing), Application (Diagnostics, Research), End-User (Research Institutes, Healthcare Facilities & Diagnostic Centers, Pharmaceutical & Biotechnological Companies, Contract Research Organization (CROs)) & Geography Forecast till 2026

Regenerative Medicine Market Share and Global Trend By By Product (Cell Therapy, Gene Therapy, Tissue Engineering, Platelet Rich Plasma), By Application (Orthopaedics, Wound Care, Oncology), By Distribution Channel (Hospitals, Clinics) & Geography Forecast till 2026

Gene Therapy Market Share & COVID-19 Impact Analysis, By Application (Oncology, Neurology, and Others), By Vector Type (Viral and Non-viral), By Distribution Channel (Hospitals, Clinics, and Others), and Regional Forecast, 2020-2027

DNA Sequencing Market Share & Industry Analysis, By Type (Instruments, Reagents & Consumables, Workflow Products, Services), By Technology (Next Generation DNA Sequencing, Sanger Sequencing), By Application (Research & Clinical Trials, Others) By End-User (Biotechnology & Pharmaceutical Industries, Diagnostic Centers, Hospitals & Clinics) and Regional Forecast, 2019-2026

Transcriptomics Market Share and Global Trend By Technology (Polymerase Chain Reaction (PCR), Microarray, Next-Generation Sequencing (NGS)), By Application (Drug Discovery, Clinical Diagnostics, Toxicogenomics), By End-User (Academic and Research Institutes, Pharmaceutical Companies, Biotechnology Companies) and Geography Forecast till 2026

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India.

Phone: US :+1 424 253 0390 UK : +44 2071 939123 APAC : +91 744 740 1245 Email: sales@fortunebusinessinsights.com Fortune Business Insights LinkedIn | Twitter | Blogs

Press Release: https://www.fortunebusinessinsights.com/press-release/next-generation-sequencing-market-9194

Link:
Next-Generation Sequencing Market Size to Reach US$ 31,411.3 Mn, Introduction of Rapid Sequencing Technologies Drives the Market: Fortune Business...

Global digital PCR market size was USD 224.9 million in 2018 and is projected to reach USD 799.1 million by 2026, exhibiting a CAGR of 17.2% during…

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Digital PCR market.

Trusted Business Insights presents an updated and Latest Study on Digital PCR Market 2019-2029. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Digital PCR market during the forecast period (2019-2029). It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Digital PCR Market Size, Share & Industry Analysis, By Type (Droplet Digital PCR, Chip-based Digital PCR, and Others), By Product (Instruments and Reagents & Consumables), By Indication (Infectious Diseases, Oncology, Genetic Disorders, and Others), By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Industries, Diagnostic Centers, and Aca-demic & Research Organizations), and Regional Forecast, 2020-2029(Includes COVID-18 Business Impact)

The global digital PCR market size was USD 224.9 million in 2018 and is projected to reach USD 799.1 million by 2026, exhibiting a CAGR of 17.2% during the forecast period.

We have updated Digital PCR Market with respect to COVID-19 Impact. Inquire before buying

Digital PCR is a biotechnological advancement of conventional PCR. It is a high-throughput absolute quantitative method that provides a sensitive and reproducible way of measuring the amount of DNA or RNA in a sample. The rise in prevalence of infectious diseases, cancer, and genetic disorders, coupled with new product launches, increasing acquisitions, and the rise in the adoption of dPCR by reference laboratories are the key factors likely to drive the market growth during the forecast period. Moreover, increasing technological advancements in digital PCR are projected to boost the global demand for dPCR products in the upcoming years.

MARKET TRENDS

Shift of Healthcare Providers from Droplet to Chip-based Digital PCR will Drive the Market The shift from droplet to chip-based digital PCR for diagnosis of various diseases has been pivotal in the advancement of dPCR devices. In commercially available droplet dPCR, the droplets have to be transferred manually, leading to underestimation of the targets. Moreover, these kits also poses a risk of cross-contamination during the transfer of the sample. On the other hand, in chip-based digital polymerase chain reaction, droplets always run in channels, reducing the risk of cross-contamination. This innovation is likely to increase its adoption for the diagnosis of various diseases in near future. Increasing incidence of infectious diseases and the growing prevalence of cancer are propelling the shift of healthcare providers for diagnosis of these conditions through chip-based digital PCR devices. This is projected to further propel the market growth during the forecast period.

MARKET DRIVERS

Technological Advancements in dPCR to Boost the Market Growth Digital polymerase chain reaction (PCR) is the refinement of conventional PCR that can be used to directly quantify and clonally amplify nucleic acids. Increasing research and development activities and growing demand for innovative devices have led to the introduction of various such technologically advanced devices offering great benefits to the Digital PCR market. The introduction of such innovative devices such as droplet, chip-based, beam, and crystal dPCR by key market players is anticipated to drive the global market growth during the forecast period. For instance, in November 2019, Bio-Rad Laboratories, Inc. announced the launch of QX ONE Droplet Digital PCR System, which provides an absolute measurement of target DNA molecules with more accuracy, precision, and sensitivity.

Growing Adoption of dPCR Over Real-time PCR to Boost the Market Globally Digital PCR helps to deliver a complete measure of target nucleic acid molecules than the relative measure achieved from the real-time PCR. This absolute DNA quantification allows for reproducibility, sensitivity, and precision, further enabling researchers to quantify smaller differences and precisely measure minor variants. These advantages are leading to growing adoption of dPCR over conventional and other PCR methods, which is likely to augment the digital PCR market growth during the forecast period.

MARKET RESTRAINT

High Cost of Digital PCR Devices and Lack of Awareness in Emerging Countries to Hamper Growth

Despite the increasing incidence of infectious diseases, cancer, and genetic disorders worldwide, and high prevalence of these conditions in emerging countries, the adoption digital polymerase chain reaction techniques is limited in these regions. This is attributable to the lack of awareness about the dPCR and its advanced types in less-developed countries. In addition to this, the high cost of these devices further restricts the market penetration. However, initiatives taken by leading players to enhance the awareness about the availability of dPCR for the diagnosis of various diseases, establishment of strong distribution network, and increased new product launches are likely to create lucrative growth opportunities for the expansion of the market in emerging regions.

SEGMENTATION

By Type Analysis

Droplet Digital PCR Dominated the Global Market

Based on type, the digital PCR market is segmented into droplet, chip-based, and others. The droplet digital polymerase chain reaction segment dominated the market in 2018. Technological advances along with various new product launches by key players have been instrumental in the dominance of droplet dPCR in the global market. For instance, in August 2018, Merck KGaA launched the BioReliance Droplet dPCR Technology for cell and gene therapy development.

Chip-based digital PCR segment is projected to register a significant CAGR during the forecast period. These dPCR devices overcome the cross-contamination drawback of droplet digital PCR leading to the increasing preference of healthcare providers for chip-based dPCR. This factor is projected to fuel the demand for this dPCR type, and drive the digital polymerase chain reaction market growth during the forecast period.

By Product Analysis

Instruments Segment to Generate the Highest Revenue During the Forecast Period In terms of product, the market is segmented into instruments, reagents & consumables. the instruments segment emerged dominant owing to their high costs. The reagents segment held comparatively low market share due to small volumes of reagents required for analysis. However, the segment is expected to grow at a significantly high growth rate owing to growing number of diagnostic procedure globally.

By Indication Analysis

Clinically Proven Effectiveness of dPCR in Infectious Diseases to Aid Dominance of the Segment In terms of indication, the market is segmented into infectious diseases, oncology, genetic disorders, and others. Among them, the infectious diseases segment is anticipated to dominate the dPCR market. The clinically proven potential advantages of droplet dPCR in diagnosis of infectious diseases, including viral, bacterial, and parasitic infections is a primary reason for the dominance of this segment in the global polymerase chain reaction (PCR) market. According to an article published by the National Center for Biotechnology Information (NCBI), dPCR provides a more sensitive, accurate, and reproducible detection of pathogens and is a better choice than real-time polymerase chain reaction for clinical applications. Oncology is among the other major indication areas for dPCR. Growing prevalence of the condition, along with the introduction of new product launches in the market is expected to drive the segment during the forecast period.

By End User Analysis

Higher Adoption of dPCR devices by Diagnostic Centers to Enable Dominance of the Segment Based on end-user, the dPCR market segments include hospitals & clinics, pharmaceutical & biotechnology industries, diagnostic centers, and academic & research organizations. The emergence of diagnostic centers for infectious diseases, genetic diseases and other conditions in developed and emerging countries is attracting a large patient pool suffering from chronic and acute conditions. The increasing number of diagnostic centers and favorable reimbursement support provided by these settings are some of the major factors responsible dominance of the segment. These are some of the factors that are responsible for the dominance of this segment throughout the forecast period.

REGIONAL ANALYSIS

The dPCR market size in North America stood at USD 96.5 million in 2018. The market in the region is characterized by high prevalence and diagnosis rates for infectious diseases. Besides this, high awareness among patient population towards new diagnostic options and availability of advanced dPCR devices in the region, are helping the region dominate the market. Moreover, the rising incidence of various types of cancer and metabolic diseases requiring advanced diagnosis and therapies are fueling the market growth in Europe. For instance, according to GLOBOCAN 2018, around 4,229,662 new cancer cases were reported in Europe. The market in Asia-Pacific is projected to register a comparatively higher CAGR during the forecast period. Growing patient awareness regarding advanced digital polymerase chain reaction devices and new product launches by market players, are projected to drive the digital polymerase chain reaction (dPCR) market in Asia Pacific during the forecast period. The market in Latin America and the Middle East & Africa is currently in nascent stage. However, the developing healthcare infrastructure in these regions and growing prevalence of infectious and genetic diseases are projected to increase the demand for the digital polymerase chain reaction products during the forecast period.

KEY INDUSTRY PLAYERS

Diverse Portfolio of Leading Players and Strong Focus on Partnerships and Acquisition to Strengthen Their Market Position

Competition landscape of the digital PCR market is consolidated with few players holding the dominant share. Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., and Sysmex Inostics are some of the leading industry players. A diversified product portfolio of droplet and chip-based digital PCR along with constant innovations by the companies, leading to new product introductions, are prominent factors responsible for the dominance of these companies. Moreover, increasing focus on partnerships and acquisition strategies in the dPCR is likely to attract more digital PCR market revenue in the future. January 2017 Bio-Rad Laboratories, Inc. acquired RainDance Technologies with an aim to expand their product portfolio in dPCR and liquid biopsy.

LIST OF KEY COMPANIES PROFILED:

KEY INDUSTRY DEVELOPMENTS:

July 2019 Sysmex Inostics launched OncoBEAM test which uses BEAMing enhanced digital PCR for liquid biopsy for cancer patients.

January 2019 QIAGEN announced plans for a global launch in 2020 of a new series of digital PCR platforms. This is based on the technology developed by FORMULATRIX combined with QIAGENs assay development expertise.

REPORT COVERAGE

The report provides a detailed analysis of the market and focuses on key aspects such as leading companies, product types, and leading applications of the product. Besides this, the report offers insights into the market trends and highlights key industry developments. In addition to the aforementioned factors, the Digital PCR market report encompasses several factors that have contributed to the growth of the market over the recent years.

Report Scope & Segmentation

Segmentation

By Type

By Product

By Indication

By End User

By Geography

Looking for more? Check out our repository for all available reports on Digital PCR in related sectors.

Quick Read Table of Contents of this Report @ Digital PCR Market Size, Share & Industry Analysis, By Type (Droplet Digital PCR, Chip-based Digital PCR, and Others), By Product (Instruments and Reagents & Consumables), By Indication (Infectious Diseases, Oncology, Genetic Disorders, and Others), By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Industries, Diagnostic Centers, and Aca-demic & Research Organizations), and Regional Forecast, 2020-2029(Includes COVID-18 Business Impact)

Trusted Business Insights Shelly Arnold Media & Marketing Executive Email Me For Any Clarifications Connect on LinkedIn Click to follow Trusted Business Insights LinkedIn for Market Data and Updates. US: +1 646 568 9797 UK: +44 330 808 0580

See the rest here:
Global digital PCR market size was USD 224.9 million in 2018 and is projected to reach USD 799.1 million by 2026, exhibiting a CAGR of 17.2% during...

Brain Stimulators Market: Rise in incidence of neurological disorders is expected to drive the market – BioSpace

Brain stimulation therapy is a procedure to treat certain mental disorders. Brain stimulation therapies involve activating or inhibiting brain activity directly with electricity. Electricity is provided directly by invasive or non-invasive brain stimulators placed on the scalp. Brain stimulators investigate the effects of electricity on basic processes such as gene expression and other aspects of molecular biology, neurochemical regulation, functional brain activity, sensorimotor function, and cognitive and affective processes. The stimulation technique uses a probe to outline patterns of neural connectivity in the brain and provides the information of brain activity in the form of graphs. The functioning of brain stimulators depends on battery powered adapter for the display of output on the patient monitor. Moreover, the system incorporates visual indicators of performance in order to provide the physicians an optimal performance. However, new developments in computer technology and rapidly growing cranial stimulation technique allows the scientific community to focus on the best practice within the medical industry, which is paving the way for early diagnosis and treatment of mental diseases.

Read Report Overview - https://www.transparencymarketresearch.com/brain-stimulators-market.html

The global brain stimulators market is driven by rapid development in technology, funding for digital health companies, rise in incidence of neurologicaldisorders, increase in government support for research & development, and adverse effects of present diagnostic & drug therapies. According to the U.S. Food and Drug Administration, deep brain stimulators were approved for treatment of movement disorders such as essential tremor, Parkinson's disease and dystonia, and recently, obsessive-compulsive disorder. Rise in prevalence of Parkinson's disease, epilepsy, dystonia, and other chronic pain is expected to drive the global brain stimulators market. However, long approval time, high cost of research & development and devices, and lack of awareness are factors expected to restrain the global brain stimulators market during the forecast period.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=52701

The global brain stimulators market can be segmented based on product type, end-user, application, and region. In terms of product type, the market can be classified into transcranial magnetic stimulators, electroconvulsive therapy stimulators, deep brain stimulators, and others. Based on application, the global brain stimulators market can be categorized into Parkinsons disease, essential tremor, dystonia, and others. In December 2017, Boston Scientific Corporation received the U.S. Food and Drug Administration (FDA) approval for the sale of Vercise Deep Brain Stimulation (DBS) System to treat the symptoms of Parkinsons disease (PD), a degenerative condition that affects more than one million people in the U.S. and 10 million globally. Hence, deep brain stimulators as an invasive device will be more prominently used in the near future. In terms of end-user, the market can be divided into diagnostic laboratories, clinics, hospitals, and others.

Request for Analysis of COVID-19 Impact on Brain Stimulators Market- https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=52701

Geographically, the global brain stimulators market can be segmented into North America, Europe, Asia Pacific, and Rest of the World. North America dominated the global market due to advanced technology used in medical devices, increase in incidence of mental illnesses among the geriatric population, significant awareness, and high per capita health care expenditure. Early-phase diagnosis, treatment of disease, and after surgery effects drive the biotechnology and medical device market which in turn is expected to propel the brain stimulators market in North America. Europe was the second largest market for brain stimulators due to favorable government policies regarding health care infrastructure, high incidence of brain diseases due to environmental conditions, and awareness programs about different types of brain disorders.The market in Asia Pacific is likely to grow at a rapid pace due to increase in the geriatric population, rise in awareness among people, and increase in per capita expenditure. Additionally, economic growth supports improvement in health care infrastructure in developing countries such as India, China, Brazil, and South Africa. Hence, these factors are expected to contribute to the growth of the brain stimulators market in Asia Pacific and Rest of the World.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=52701

Major players operating in the global brain stimulators market include Medtronic plc, Boston Scientific Corporation, Abbott Laboratories, Aleva Neurotherapeutics SA, Deep Brain Innovations, LLC, and SceneRay.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Pre Book Brain Stimulators Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=52701&ltype=S

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industrys value chain.

Browse More Trending Reports by Transparency Market Research:

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Mr. Rohit Bhisey Transparency Market Research

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

Continue reading here:
Brain Stimulators Market: Rise in incidence of neurological disorders is expected to drive the market - BioSpace

Global mucopolysaccharidosis treatment market size was USD 1.98 billion in 2018 and is projected to reach USD 4.37 billion by 2026, exhibiting a CAGR…

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Mucopolysaccharidosis Treatment market.

Trusted Business Insights presents an updated and Latest Study on Mucopolysaccharidosis Treatment Market 2019-2029. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Mucopolysaccharidosis Treatment market during the forecast period (2019-2029). It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Mucopolysaccharidosis Treatment Market Size, Share & Industry Analysis, By Treatment (Enzyme Replacement Therapy (ERT), and Others), By Disease Type (Mucopolysaccharidosis Type I, Mucopolysaccharidosis Type II, Mucopolysaccharidosis Type IV A, Mucopolysaccharidosis Type VI, and Others), By Route of Administration (Intravenous, and Intracerebroventricular (ICV)), By End User (Hospitals, Specialty Clinics, and Others), and Regional Forecast, 2020-2029(Includes COVID-18 Business Impact)

The global mucopolysaccharidosis treatment market size was USD 1.98 billion in 2018 and is projected to reach USD 4.37 billion by 2026, exhibiting a CAGR of 10.4% during the forecast period.

We have updated Mucopolysaccharidosis Treatment Market with respect to COVID-19 Impact. Inquire before buying

MPS, also known as mucopolysaccharidosis, refers to a group of key rare metabolic disorders which is caused by the absence, deficiency or malfunctioning of lysosomal enzymes called glycosaminoglycan (GAGs). This inability to completely down the sugar, leads to the abnormal accumulation of certain compounds such as dermatan sulfate, heparan sulfate, and keratan sulfate, which interferes with normal cell function of the body. One of the characteristic symptoms of MPS is the presence of severe neurological symptoms that are present in several types of MPS such as Hunter syndrome and Sanfilippo syndrome and a number of clinical stage companies are involved in the R&D of new therapeutics for the management of these symptoms.MARKET TRENDSIncreasing R&D for Rare Diseases to Drive the Market GrowthMarket trends present in the mucopolysaccharidosis (MPS) treatment market is the increasing number of pipeline candidates from major companies in the therapeutic area of rare diseases or orphan diseases. Since, mucopolysaccharidosis is considered to be a potentially serious orphan disease group, some prominent clinical stage biopharmaceutical companies such as ArmaGen and REGENXBIO Inc. are involved in the clinical trials for new therapeutics. This increasing initiatives into the development of rare diseases therapies is due to the fact that development of major blockbuster drugs is more possible in these rare diseases as compared to the conventional pharmaceutical portfolios. Another driving factor for this trend is that the pharmaceutical companies are mandated to conduct larger outcome studies for conventional medications or therapies. This is applicable for therapies to treat diseases such as heart disease and diabetes in comparison to rare disorders such as the several disease types of mucopolysaccharidosis. This is projected to further positively drive the mucopolysaccharidosis treatment market growth during the forecast period.

MARKET DRIVERS

Need for Advanced Therapeutics Due to Unmet Clinical Needs and Better Treatment Outcomes to Propel Market GrowthThe lack of presence of a wide range of therapeutics for the patients, which has led to the creation of the monopoly of one type of therapy, enzyme replacement therapy is the most critical driver for the market growth. For instance, for the treatment of mucopolysaccharidosis type II (Hunter syndrome), Elaprase is the most commonly used therapeutic, an enzyme replacement therapy (ERT). This ERT is a prohibitively expensive therapy option and often patients from developing countries cannot easily access this therapeutic due to cost constraints. Other therapeutics for MPS treatment include Vimizim (elosulfase alfa) which is administered for the treatment of MPS IV A (Morquio syndrome) and which at the time of launch in the market is estimated to cost US$ 380,000 for the disorders annual treatment. Hence, due to the six-figure costs of most of the enzyme replacement therapy (ERT), the patients in the emerging countries such as India, often cannot afford these therapeutics despite increasing initiatives for improved access from various governments. Anticipated launches of cheaper alternatives and advanced therapeutics is anticipated to drive the growth of the global MPS treatment market during the forecast period.Another critical driving factor is the increasing need for advanced therapeutics due to unmet clinical needs and better treatment outcomes. During the current period therapeutics, such as Elaprase, and ALDURAZYME are not capable of crossing the blood-brain barrier, a key requirement for effective management of the disorder. So, these therapeutics are not able to appropriately address the neurological symptoms and complications of the patients of mucopolysaccharidosis (MPS), who are most severely affected. For instance, in the patients of Hunter syndrome with the most severe symptoms, which affects approximately two-thirds of the total patient population, the neurological symptoms are severely disabling. The therapeutics used currently are not able to treat the neurological symptoms, thus a significant proportion of the population remains in the need for appropriate treatment. This is anticipated to propel the demand for effective therapeutics which aid in the management of all types of the symptoms of the mucopolysaccharidosis and drive the growth of the MPS treatment market size during the forecast period.Increasing Number of Clinical Stage Candidates in R&D Pipelines of Major Players to Drive MarketThere is a significant number of pipeline candidates for the development of advanced therapeutics for an increasing number of rare disorders and the several types of mucopolysaccharidosis is one of the key disease groups for these companies due to the severity of the disease. According to the National Organization for Rare Disorders (NORD) (NORD), the prevalence of all disease types of mucopolysaccharidosis is estimated to be 1 in 25,000 births. In April 2019, it was reported that in Japan, an estimated 150 individuals suffered from mucopolysaccharidosis type II (Hunter syndrome). Such driving factors are further leading to the presence of prominent and important pipeline candidates. ArmaGen, Denali Therapeutics, and REGENXBIO Inc., all have pipeline candidates for the various types of MPS in various stages of clinical trials. The above factors combined with the need for advanced therapeutics is further anticipated to drive the demand for these therapeutics and stimulate the MPS market growth.MARKET RESTRAINTHigh Cost Therapeutics Coupled with Poorer Diagnosis Rates and Low Treatment Rates in Emerging Countries to Restrain the Market In recent times, globally due to sophistication in diagnostics, there is a higher prevalence of MPS in several countries which includes emerging regions such as Asia, there are certain factors that are restraining the widespread usage of these therapies. Due to the high costs associated with enzyme replacement therapies (ERT), which is the mainstay treatment for MPS, one of the major factors limiting the growth of the market is low levels treatment rates in emerging countries. This severely limits the number of patients undergoing treatment, and a significant proportion of the patients of MPS are left without treatment due to their inability to afford treatment. Often, these therapies are not available to the patients in the developing countries due to lack of awareness and also options for the payment of these therapies. The governments in these countries often do not have appropriate awareness regarding these diseases and do not adequately reimburse them. Another key limiting factor is the delays associated with the diagnosis of mucopolysaccharidosis. A study published in 2018, in the Orphanet Journal of Rare Diseases, indicated that there is a failure to shorten the diagnostic delay in the two ultra-orphan diseases of mucopolysaccharidosis types I and mucopolysaccharidosis type III. Factors as such are further expected to restrain the market growth.SEGMENTATIONBy Treatment AnalysisEnzyme Replacement Therapy (ERT) is Expected to Dominate the Global MarketBased on treatment, the global market is segmented into enzyme replacement therapy (ERT), and others. The primary treatment for lysosomal storage disorders, a group of disorders to which MPS belongs, is enzyme replacement therapy (ERT). These enzyme replacement therapies, aim to replace or generate the missing or deficient enzyme in the body, due to which mucopolysaccharidosis occurs. Hence, the enzyme replacement therapy (ERT) segment dominated the mucopolysaccharidosis treatment market share in 2018. The only major therapeutics approved by the regulatory agencies globally treatment of MPS, is enzyme replacement therapy (ERT). For example, in case of mucopolysaccharidosis type II (Hunter syndrome), the only two approved products are Elaprase and Hunterase which are both ERTs, and have been instrumental in the dominance of this segment in the global market.The others segment is anticipated to grow at a comparatively stronger CAGR. The mucopolysaccharidosis (MPS) treatment market growth during the forecast period is anticipated to be driven by the growing number of clinical trials involving the usage of the hematopoietic stem cell transplant (HSCT). Other than stem cell transplantation, a number of prominent clinical stage biopharmaceutical companies are conducting trials on gene therapy including Sangamo Therapeutics, which has a pipeline candidate for Hunter syndrome.By Disease Type Analysis To know how our report can help streamline your business, Speak to Analyst var get_chart_name1=

MPS II (Hunter Syndrome) to Dominate the Disease Type due to Presence of Key Products In terms of disease type, the market is segmented into mucopolysaccharidosis type I also known as Hurler syndrome/Hurler-Scheie syndrome/Scheie syndrome, mucopolysaccharidosis type II also known as Hunter syndrome, mucopolysaccharidosis type IV A also known as Morquio A syndrome, mucopolysaccharidosis Type VI also known as MaroteauxLamy syndrome, and others. The mucopolysaccharidosis type II (Hunter Syndrome) is expected to dominate the market due to the presence of key products such as Hunterase and Elaprase. Both of these products accounts for a significant portion of the market revenue share. The other segments in the global mucopolysaccharidosis treatment market which includes mucopolysaccharidosis type I, mucopolysaccharidosis type IV A and mucopolysaccharidosis Type VI, all of which have key products offerings attributable to them. Such factors are anticipated to drive the market during the forecast period.The others segment includes mucopolysaccharidosis type VII (Sly syndrome) whose product offering of MEPSEVII (vestronidase alfa-vjbk) is anticipated to register a strong growth rate during the forecast period. Growing prevalence of the mucopolysaccharidosis types, along with introduction of major enzyme replacement therapy (ERT) products in the market, is expected to drive the growth of the segment during the forecast period.By Route of Administration AnalysisPresence of Major Therapeutics in Intravenous Form to Aid Dominance of the SegmentIn terms of route of administration, the market is segmented into intravenous, and intracerebroventricular (ICV). The intravenous type is anticipated to account for the majority of the revenue share of the route of administration segment, because most of the therapeutics for MPS treatment are to be administered through intravenous injections only. For example, the most prominent therapeutic for Hunter syndrome, Elaprase is administered intravenously. Intravenous therapeutics holds a monopoly over the mucopolysaccharidosis treatment market and is anticipated to hold control over its market share in the forecast period.The only other approved therapeutic that is not in an intravenous form and the route of administration is intracerebroventricular (ICV), is Hunterase. Growing approvals in other countries of these therapeutic, along with anticipated introduction in other countries across the globe, is expected to drive the growth of the segment during the forecast period.By End User AnalysisIncreased Need for Administration of Therapeutics at Hospitals to Enable Dominance of the SegmentOn the basis of end user, the market is segmented into hospitals, specialty clinics, and others. The key factor aiding in the dominance of hospitals segment is that the therapeutics used in MPS treatment can often be administered by trained medical professionals who can administer these therapeutics in settings such as hospitals with care and proper guidelines. This allows for the proper adherence to the MPS treatment guidelines and administration of critical therapeutics which have to be administered intravenously, in a safe environment to manage the increased risk of infusion site infections.Growing number of specialty clinics, due to increasing need for specialist care of a higher degree for the treatment and management of several types of mucopolysaccharidosis (MPS) patients, are some of the major factors responsible for this segments dominance forecast period. Also, a number of these specialty clinics are based in the developed countries, resulting in a strong market revenue share. Also, the increasing government initiatives such as the Brazilian Governments initiative for the setting up of treatment guidelines is also anticipated to contribute to the segments growth.

REGIONAL ANALYSISNorth

segmentation(get_label12,get_values2,chartid);The mucopolysaccharidosis (MPS) treatment market size in North America stood at USD 1,019.4 million in 2018. Some of the characteristics of this market is higher diagnosis and treatment rates for a number of rare disorders, coupled with adequate reimbursement policies for these therapeutics. These factors, coupled with higher awareness among patient population towards advanced treatment options, increasing diagnostic sophistication, presence of significant clinical trials, and the presence of major clinical stage biopharmaceutical companies are their pipeline candidates, are responsible for highest share of the region in the global market. The market in Europe is anticipated to account for the second largest revenue share during the forecast period. The presence of key products in the region such as Elaprase and ALDURAZYME, is anticipated to drive the demand for MPS treatment in Europe during 2019-2026. Asia-Pacific is projected to register the highest CAGR during the forecast period. Anticipated launch of some therapeutics such as Hunterase in Japan in Asia Pacific, the upcoming product launches in the region due to increased regulatory applications for approvals, and the presence of a strong potential patient population base in the region, together are projected to fuel the mucopolysaccharidosis (MPS) treatment market growth in Asia Pacific during forecast period. The rest of the world market comprises of Latin America and the Middle East & Africa and is currently in nascent stage. However, developing healthcare infrastructure in these regions, increased government initiatives and growing awareness of rare disorders is projected to fuel the mucopolysaccharidosis treatment market demand during forecast period.KEY INDUSTRY PLAYERSKey Product Offerings and Core Focus on Mucopolysaccharidosis of Shire (Takeda Pharmaceutical Company Limited) and BioMarin, to Propel the Company to a Leading Position Competition landscape of mucopolysaccharidosis (MPS) treatment market depicts a competitive landscape dominated by a few key players. Shire (now owned by Takeda Pharmaceutical Company Limited), whose prominent product of Elaprase commands a strong revenue share, and BioMarin are some of the key market players. For example, the product offering of Shire (Takeda Pharmaceutical Company Limited) of Elaprase (idursulfase), its efficiency in terms of treatment outcomes and also its indispensability in treatment of MPS II, are prominent factors responsible for the dominance of the company in the mucopolysaccharidosis treatment. BioMarin has the key product offerings of ALDURAZYME, VIMIZIM, and NAGLAZYME in its product portfolio, covering three types of mucopolysaccharidosis.However, ArmaGen, and REGENXBIO Inc., are some of the prominent clinical stage biopharmaceutical companies such who have entered the clinical trials with their potential drug candidates. This is projected to positively impact the global market as these companies are poised to gain market share during the forecast period through key regulatory approvals.LIST OF KEY COMPANIES PROFILED :Shire (Takeda Pharmaceutical Company Limited)Denali TherapeuticsArmaGenREGENXBIO Inc.Sangamo TherapeuticsBioMarinLysogeneAbeona Therapeutics Inc.Ultragenyx PharmaceuticalGenzyme CorporationOthersKEY INDUSTRY DEVELOPMENTS:February 2020 Lysogene, a key clinical stage biopharmaceutical company, received the FDA fast track designation for the pipeline candidate of LYS-SAF302 gene therapy in MPS IIIA, also known as the Sanfilippo syndrome.April 2019 Abeona Therapeutics, a key integrated leader in cell and gene therapy development, received the FDA Fast Track Designation for their pipeline candidate of ABO-101 for the treatment of Sanfilippo syndrome type B or MPS IIIB.August 2018 Ultragenyx announced the approval of Mepsevii (vestronidase alfa) in Europe for the treatment of mucopolysaccharidosis VII, also known as Sly syndrome.REPORT COVERAGEThe mucopolysaccharidosis treatment market report provides a detailed analysis of the market and focuses on key aspects such as prevalence of key mucopolysaccharidosis types by key regions (2018), pipeline analysis, key industry developments, regulatory scenario- by key regions, overview of emerging treatments for mucopolysaccharidosis, and reimbursement scenario by key regions. Besides this, the report offers insights into the market trends and highlights key industry developments. In addition to the aforementioned factors, the report encompasses several factors that have contributed to the growth of the market over the recent years.

Report Scope & Segmentation

ATTRIBUTEDETAILSStudy Period 2015-2026Base Year 2018Forecast Period 2019-2026Historical Period 2015-2017Unit Value (USD billion)SegmentationBy TreatmentEnzyme Replacement Therapy (ERT)OthersBy Disease TypeMucopolysaccharidosis Type IMucopolysaccharidosis Type IIMucopolysaccharidosis Type IV AMucopolysaccharidosis Type VIOthersBy Route of Administration IntravenousIntracerebroventricular (ICV)By End User HospitalsSpecialty ClinicsOthersBy GeographyNorth America (U.S. and Canada)Europe (U.K., Germany, France, Italy, Spain, and Rest of Europe)Asia-Pacific (Japan, China, India, South Korea, and Rest of Asia-Pacific)Rest of the World

Looking for more? Check out our repository for all available reports on Mucopolysaccharidosis Treatment in related sectors.

Quick Read Table of Contents of this Report @ Mucopolysaccharidosis Treatment Market Size, Share & Industry Analysis, By Treatment (Enzyme Replacement Therapy (ERT), and Others), By Disease Type (Mucopolysaccharidosis Type I, Mucopolysaccharidosis Type II, Mucopolysaccharidosis Type IV A, Mucopolysaccharidosis Type VI, and Others), By Route of Administration (Intravenous, and Intracerebroventricular (ICV)), By End User (Hospitals, Specialty Clinics, and Others), and Regional Forecast, 2020-2029(Includes COVID-18 Business Impact)

Trusted Business Insights Shelly Arnold Media & Marketing Executive Email Me For Any Clarifications Connect on LinkedIn Click to follow Trusted Business Insights LinkedIn for Market Data and Updates. US: +1 646 568 9797 UK: +44 330 808 0580

View post:
Global mucopolysaccharidosis treatment market size was USD 1.98 billion in 2018 and is projected to reach USD 4.37 billion by 2026, exhibiting a CAGR...